Analysis offers new hope for failed fragile X drug
Eye tracking shows that mavoglurant, a once-abandoned experimental drug for fragile X syndrome, enters the brain and boosts social interest, says Elizabeth Berry-Kravis.
Eye tracking shows that mavoglurant, a once-abandoned experimental drug for fragile X syndrome, enters the brain and boosts social interest, says Elizabeth Berry-Kravis.
People with autism may show scant activity in a poorly understood molecular process thought to regulate gene expression.
Many countries in Europe are reckoning with the growing demand for genetic tests for autistic people — and the accompanying ethical and scientific considerations.
Una remota ciudad colombiana es el hogar del grupo más grande de personas con síndrome de X frágil. Los científicos están aprendiendo de ellos y tratando de ayudar.
Genetic tests for people with autism are far from routine and don’t always yield results, but the information they offer can change lives.
Spectrum’s editors chose five stories from 2018 you may have missed the first time around.
This year’s list of top papers highlights new dimensions in our understanding of autism genetics and hints at novel treatments.
Carriers of fragile X premutations in Ricaurte, Colombia, have more medical problems than carriers living elsewhere — and discovering why might yield treatments for the syndrome.
Administering a cholesterol drug alongside an antibiotic eases atypical behavior and restores the signaling balance in the brains of people with fragile X syndrome.
The motion perception difficulties seen in people with fragile X syndrome, a leading cause of autism, may stem from a faulty visual circuit.